Novo Nordisk A/S (NYSE:NVO) Stock Holdings Boosted by Grove Bank & Trust

Grove Bank & Trust lifted its position in Novo Nordisk A/S (NYSE:NVOFree Report) by 14.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,312 shares of the company’s stock after buying an additional 1,669 shares during the period. Grove Bank & Trust’s holdings in Novo Nordisk A/S were worth $1,585,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of NVO. Integrated Advisors Network LLC boosted its position in shares of Novo Nordisk A/S by 56.6% during the 4th quarter. Integrated Advisors Network LLC now owns 8,478 shares of the company’s stock valued at $877,000 after purchasing an additional 3,063 shares in the last quarter. Richardson Financial Services Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $38,000. SageView Advisory Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $271,000. Leo Wealth LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $565,000. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth $1,876,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.3 %

Shares of Novo Nordisk A/S stock traded down $0.38 on Monday, hitting $119.66. 1,248,310 shares of the company traded hands, compared to its average volume of 4,309,590. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a 12-month low of $92.94 and a 12-month high of $148.15. The company has a 50-day moving average price of $129.39 and a 200 day moving average price of $132.04. The company has a market cap of $536.98 billion, a PE ratio of 41.29, a PEG ratio of 1.53 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Sell-side analysts predict that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is 24.83%.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $145.17.

Check Out Our Latest Report on NVO

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Further Reading

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.